PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Clinical trial NCT06900218 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06900218
- Sponsor
- Sun Yat-sen University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-01
- Primary completion
- 2030-05-01
- Enrollment
- 664
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.